PharmaSGP Holding SE / Key word(s): Personnel PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer 05-Nov-2024 / 10:02 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January 1, 2025. This was decided by the Supervisory Board today. Peter Gerckens succeeds Natalie Weigand in this position. She informed the Supervisory Board today that she has decided not to extend her contract, which expires at the end of the year. However, Natalie Weigand will remain associated with the company in an advisory role after her departure. * * * Contact PharmaSGP Holding SE End of Inside Information 05-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 | Psychedelic Invest
NEW YORK and BERLIN, March 04, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment